Neoadjuvant chemotherapy (NAC) with the addition of pembrolizumab has become the standard of care for early-stage II-III triple-negative breast cancer (TNBC). The real-world safety of this regimen is critical to assess in this subset of patients treated with curative intent, since many of the immune-related events observed can be long-lasting or irreversible. We retrospectively analyzed the medical records for the initial 100 patients with early-stage TNBC treated with NAC and pembrolizumab at a single comprehensive cancer center between April 2022 and April 2023. We used descriptive analyses to assess treatment exposure, real-world safety and effectiveness of this combination. Treatment-related toxicities were reported according to the Common Terminology Criteria for Adverse Events v5.0. Follow-up extended until the end of the adjuvant phase. The median age of the patients was 52 years, and 21% were identified as germline pathogenic BRCA1 /2 alteration carriers. Treatment discontinuation rate due to adverse events (AEs) in the neoadjuvant phase was 35%. Half of the patients (50%) required dose reductions of at least one chemotherapy drug. The total rate of pathological complete response/residual cancer burden 0 was 58%. A total of 61% experienced at least one immune-related AE (irAE), 30% of which were grade 3-5. We documented one grade 5 toxicity following immune-related myocarditis. In this real-life cohort, treatment discontinuation was frequent and linked to treatment toxicity of either chemotherapy or pembrolizumab. We report a higher rate of all grade and grade ≥3 irAEs as compared to the rates documented in the pivotal KEYNOTE 522 trial. The effectiveness of neoadjuvant chemo-immunotherapy for the treatment of stage II-III TNBC was similar to that reported in the literature.
30 December 2025 in European Journal of Surgical Oncology
Metastatic triple-negative breast cancer (mTNBC) remains a major therapeutic challenge, particularly among older women, who are frequently underrepresented in clinical trials. This study aimed to describe the characteristics, treatment patterns, and prognostic factors for real-world progression-free survival (rwPFS) and overall survival (OS) in older (≥70 years) women with metastatic TNBC (mTNBC) compared to younger women. (40-69 years) METHODS: A retrospective analysis of the UNICANCER ESME cohort was conducted, including 4246 women diagnosed with mTNBC between 2008 and 2021. Patient demographics, tumor characteristics, treatment data, and survival outcomes were collected. Kaplan-Meier survival analysis and Cox proportional hazards models were used to assess OS and rwPFS. Older women (n = 987) presented with less aggressive tumors and were less likely to receive chemotherapy or targeted therapy compared to younger women (n = 3259). Median OS was 13.7 months in older women and 15.8 months in younger women, with no significant difference. Prognostic factors for OS and rwPFS included the number of metastatic sites, visceral metastasis, and metastasis-free interval, regardless of age. In older women, age over 80 was associated with poorer prognosis. Despite differences in treatment patterns, survival outcomes were comparable between older and younger women with mTNBC. This real-world analysis underscores the importance of studying mTNBC in older populations, who are often excluded from clinical trials. Further research is needed to optimize treatment strategies for older women with mTNBC, especially with the introduction of new therapies and considering the real world data that allows for a better understanding of this population.